In line with the inhibitory effects observed on N‐Myc protein levels following IBL‐302 treatment, PIM/PI3K targeting might have a stronger effect against MYCN‐amplified neuroblastoma as compared to non‐MYCN‐amplified tumors. This evidence concerns the gene MYCN and neuroblastoma.